From Wikipedia, the free encyclopedia
Jump to: navigation, search
MiR-143 secondary structure.png
miR-143 microRNA secondary structure and sequence conservation
Symbol mir-143
Rfam RF00683
miRBase family MIPF0000094
Entrez 406935
HUGO 31530
OMIM 612117
Other data
RNA type microRNA
Domain(s) Eukaryota; Vertebrata
SO {{{SO}}}

In molecular biology mir-143 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by a several mechanisms. mir–143 is highly conserved in vertebrates.[1] mir-143 is thought be involved in cardiac morphogenesis but has also been implicated in cancer.

Genomic location[edit]

mir– 143 is located on chromosome 5 position 33 in the human genome.[1] mir-143 is located very close to mir-145 in the genome and it is speculated that they are transcribed as a bicistronic unit.[2] Their co-transcription means they are frequently studied together in the same cellular pathways and diseases.


mir–143 is a direct transcriptional target of the serum response factor, myocardin and nkx2-5.[2] mir-143 expression is also thought to be controlled epigenetically through heart beat.[3]


These are known genetic targets for mir–143 and its effect on them:

  • Klf4 - Promotes transcription.[2]
  • ELK1 – Promotes transcription.[2]
  • ADD3 – Represses transcription. F-actin capping protein.[4]
  • FNDC38 – Represses transcription. Tumour metastasis.[5]
  • Raldh2/aldh1a2 - Represses transcription. Involved in heart tube organization.[3]
  • rxrab – Represses transcription. Involved in heart tube organization.[3]
  • KLF5 – Unknown has conserved miR – 143 binding site.[1]
  • MAP3K7– Unknown has conserved miR – 143 binding site.[1]
  • TARDBP – Unknown has conserved miR – 143 binding site.[1]
  • UBE2E3– Unknown has conserved miR – 143 binding site.[1]


mir-143 is thought to play an important role in cardiac morphogenesis. mir–143 was found to be the most enriched miRNA in mouse embryonic stem cells that were differentiating into cardiac progenitor cells.[2] It is a direct transcriptional target of serum response factor, myocardin and nkx2-5.[2] Research has shown that mir-143 plays an important role in smooth muscle cell fate. It is co-transcribed with miR-145 in cardiac progenitors before becoming vascular smooth muscle cells (VSMCs). VSMCs are unusual in the fact that they can switch between a proliferative or a quiescent more differentiated state. Along with mir–145, mir- 143 has been shown to target a network of transcription factors (including klf4 and elk-1) that promote differentiation and repress the proliferation of VSMCs.[2] MiR-143 has also been implicated in the more general morphogenesis of the heart. In zebrafish it was shown that mir-143 is required for chamber morphogenesis through repression of add3. A knockout resulted in ventricular collapse.[4] It has also been suggested that mir-143 expression may be controlled by heart beat. In zebrafish mir-143 expression was absent when heartbeat was arrested and restored when heartbeat was reinitiated.[3] Understanding mir– 143 may be important for understanding vascular disease. The plasticity of VSMCs is thought to be the basis of many human vascular diseases such as atherosclerosis.[2] It has also been shown that in human aortic aneurysms the expression of mir-143 and mir-145 were found to be significantly decreased when compared to controls.[6]


Changes in mir-143 expression have frequently been implicated in cancer. However the exact nature of this relationship is not fully understood. The up-regulation of mir-143 was observed in a hepatocellular carcinoma model during tumor metastasis through repression of FNDC38.[5] However decreased expression of mir-143 and 145 have been observed in cancer samples. Expression was shown to be decreased in a range of cancer stages, including in very early samples. This suggests that they are involved in tumorgenesis.[7] A modified version of mir-143 (mir-143BP) with greater activity and resistance to nuclease was shown to have a tumor-suppressive effect on colorectal cancer cells. This makes miR-143 a candidate for RNA medicine for treatment of tumors.[7]


[1] [2] [3] [4] [5] [6] [7]

  1. ^ a b c d e f g Trakooljul N, Hicks JA, Liu HC (2010). "Identification of target genes and pathways associated with chicken microRNA miR-143.". Anim Genet. 41 (4): 357–64. doi:10.1111/j.1365-2052.2009.02015.x. PMID 20064147. 
  2. ^ a b c d e f g h i Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D (2009). "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity". Nature. 460 (7256): 705–10. doi:10.1038/nature08195. PMC 2769203Freely accessible. PMID 19578358. 
  3. ^ a b c d e Miyasaka KY, Kida YS, Banjo T, Ueki Y, Nagayama K, Matsumoto T, Sato M, Ogura T (2010). "Heartbeat regulates cardiogenesis by suppressing retinoic acid signaling via expression of miR-143". Mech Dev. 128 (1–2): 18–28. doi:10.1016/j.mod.2010.09.002. PMID 20869435. 
  4. ^ a b c Deacon DC, Nevis KR, Cashman TJ, Zhou Y, Zhao L, Washko D, Guner-Ataman B, Burns CG, Burns CE (2010). "The miR-143-adducin3 pathway is essential for cardiac chamber morphogenesis". Development. 137 (11): 1887–96. doi:10.1242/dev.050526. PMID 20460367. 
  5. ^ a b c Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F (2010). "microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2". Oncol Rep. 24 (5): 1363–9. doi:10.3892/or_00000994. PMID 20878132. 
  6. ^ a b Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G (2009). "The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease". Cell Death Differ. 16 (12): 1590–8. doi:10.1038/cdd.2009.153. PMC 3014107Freely accessible. PMID 19816508. 
  7. ^ a b c Kitade Y, Akao Y (2010). "MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and -145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug". J Pharmacol Sci. 114 (3): 276–80. doi:10.1254/jphs.10R12FM. PMID 20953119. 

Further reading[edit]

External links[edit]